Synaptogenix Ownership
SNPX Stock | USD 4.45 0.01 0.23% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Synaptogenix |
Synaptogenix Stock Ownership Analysis
The company has price-to-book ratio of 0.21. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Synaptogenix recorded a loss per share of 23.73. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 5th of April 2024. Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company was incorporated in 2012 and is headquartered in New York, New York. Synaptogenix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. To find out more about Synaptogenix contact MBA MD at 973 242 0005 or learn more at https://www.synaptogen.com.Besides selling stocks to institutional investors, Synaptogenix also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Synaptogenix's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Synaptogenix's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Synaptogenix Quarterly Liabilities And Stockholders Equity |
|
Roughly 2.0% of Synaptogenix are currently held by insiders. Unlike Synaptogenix's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Synaptogenix's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Synaptogenix's insider trades
Synaptogenix Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Synaptogenix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Synaptogenix backward and forwards among themselves. Synaptogenix's institutional investor refers to the entity that pools money to purchase Synaptogenix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Orion Capital Management Llc | 2023-12-31 | 2 K | Ubs Group Ag | 2023-12-31 | 1.8 K | Blackrock Inc | 2023-12-31 | 942 | Acadian Asset Management Llc | 2023-12-31 | 591 | Tower Research Capital Llc | 2023-12-31 | 386 | Newbridge Financial Services Group, Inc. | 2023-12-31 | 300 | Wells Fargo & Co | 2023-12-31 | 149 | Royal Bank Of Canada | 2023-12-31 | 118 | 1832 Asset Management L.p | 2023-12-31 | 25.0 | Renaissance Technologies Corp | 2023-12-31 | 540.9 K | Geode Capital Management, Llc | 2023-12-31 | 154.5 K |
Synaptogenix Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Synaptogenix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Synaptogenix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Synaptogenix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Silverman Joshua over two weeks ago Acquisition by Silverman Joshua of 800 shares of Synaptogenix at 5. subject to Rule 16b-3 | ||
Bernstein Bruce over a month ago Acquisition by Bernstein Bruce of 800 shares of Synaptogenix at 5. subject to Rule 16b-3 | ||
Bernstein Bruce over a year ago Acquisition by Bernstein Bruce of 20000 shares of Synaptogenix subject to Rule 16b-3 |
Synaptogenix Corporate Filings
10Q | 15th of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 10th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 4th of April 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 1st of April 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Synaptogenix offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Synaptogenix's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Synaptogenix Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Synaptogenix Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Synaptogenix. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Synaptogenix Stock please use our How to Invest in Synaptogenix guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Synaptogenix Stock analysis
When running Synaptogenix's price analysis, check to measure Synaptogenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synaptogenix is operating at the current time. Most of Synaptogenix's value examination focuses on studying past and present price action to predict the probability of Synaptogenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synaptogenix's price. Additionally, you may evaluate how the addition of Synaptogenix to your portfolios can decrease your overall portfolio volatility.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Synaptogenix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Synaptogenix. If investors know Synaptogenix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Synaptogenix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (23.73) | Return On Assets (0.13) | Return On Equity (0.16) |
The market value of Synaptogenix is measured differently than its book value, which is the value of Synaptogenix that is recorded on the company's balance sheet. Investors also form their own opinion of Synaptogenix's value that differs from its market value or its book value, called intrinsic value, which is Synaptogenix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Synaptogenix's market value can be influenced by many factors that don't directly affect Synaptogenix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Synaptogenix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Synaptogenix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Synaptogenix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.